Caring Ambassadors Hepatitis C
Program Newsletter
www.HepCChallenge.org
September
2009
Clinical Trials, Cohort Studies,
Pilot Studies
Validation
of three non-invasive markers in assessing the severity of liver fibrosis in
chronic hepatitis C. Shaikh S,
Memon MS, Ghani H, et al. J Coll Physicians Surg Pak. 2009 Aug;19(8):478-82
Ethnicity
and body mass Iindex are associated with hepatitis C presentation and progression.
Kallwitz ER, Layden-Almer J,
Dhamija M, et al. Clin Gastroenterol Hepatol. 2009 Aug 14. [Epub ahead of
print]
Focal
distribution of hepatitis C virus RNA in infected livers. Stiffler JD, Nguyen M, Sohn JA, Liu C, Kaplan
D, Seeger C. 36: PLoS One. 2009 Aug 18;4(8):e6661.
Laparoscopic
splenectomy with peginterferon and ribavirin therapy for patients with
hepatitis C virus cirrhosis and hypersplenism. Akahoshi T, Tomikawa M, Korenaga D, et al. Surg Endosc. 2009 Aug 19.
[Epub ahead of print]
Factors
influencing long-term changes of mental health after interferon-alpha treatment
of chronic hepatitis C. Schmidt F,
Janssen G, Martin G, et al. Aliment Pharmacol Ther. 2009 Aug 18. [Epub ahead of
print]
Efficacy
and tolerability of rituximab with or without PEGylated interferon alfa-2b plus
ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup
study of thirty-two patients. Terrier
B, Saadoun D, Sène D, et al. Arthritis Rheum. 2009 Aug;60(8):2531-40.
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon. Adinolfi LE, Durante-Mangoni E, Salzillo M, et al. Intern Emerg Med. 2009 Aug 1. [Epub ahead of print]
Basic and Applied Science,
Pre-Clinical Studies
Genetic
variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge1, Jacques Fellay1, Alexander J.
et al. Nature advance online publication 16 August 2009
http://www.nature.com/nature/journal/vaop/ncurrent/full/nature08309.html
Endotoxin
receptor CD14 gene variants and histological features in chronic HCV infection.
Askar E, Ramadori G, Mihm S. World J Gastroenterol. 2009 Aug
21;15(31):3884-90.
Modulations of cell cycle checkpoints in HCV associated disease. Sarfraz S, Hamid S, Ali S, Jafri W, Siddiqui A. BMC Infect Dis. 2009 Aug 10;9(1):125
Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM. BMC Med Genomics. 2009 Aug 8;2(1):51. [Epub ahead of print]
Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. Bekker V, Chanock SJ, Yeager M, et al. J Viral Hepat. 2009 Aug 7. [Epub ahead of print]
HIV/HCV Coinfection
Treat
early or wait and monitor? A qualitative analysis of provider hepatitis C virus
treatment decision-making in the context of HIV coinfection. Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz
M, Witt M. AIDS Patient Care STDS. 2009 Aug 10. [Epub ahead of print]
Management
of hepatitis C virus infection in HIV/HCV co-infected patients: clinical
review. Singal AK, Anand BS.
World J Gastroenterol. 2009 Aug
14;15(30):3713-24.
Determination
of hepatitis C virus-infected, monocyte lineage reservoirs in individuals with
or without HIV coinfection. Coquillard
G, Patterson BK. J Infect Dis. 2009 Sep 15;200(6):947-54.
http://www.ncbi.nlm.nih.gov/pubmed/19678757
Occult hepatitis
B virus infection in a cohort of HIV-positive patients: Correlation with
hepatitis C virus coinfection, virological and immunological features. Morsica G, Ancarani F, Bagaglio S, et al. Infection.
2009 Aug 7. [Epub ahead of print]
Longitudinal
evaluation of viral interactions in treated HIV-hepatitis B co-infected
patients with additional hepatitis C and D virus. Boyd A, Lacombe K, Miailhes P, et al. J Viral Hepat. 2009 Aug 4. [Epub
ahead of print]
Diagnosis
of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new
noninvasive index: the HGM-3 index. Resino
S, Micheloud D, Miralles P,et al. HIV Med. 2009 Aug 3. [Epub ahead of print]
Epidemiology, Diagnostics, and Miscellaneous
Works
Quality
of life considerations for patients with chronic hepatitis C. Foster GR. J Viral Hepat. 2009
Sep;16(9):605-11. Epub 2009 Aug 5.
Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. Tsui JI, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Drug Alcohol Depend. 2009 Jul 30. [Epub ahead of print]
The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. Pang PS, Planet PJ, Glenn JS. PLoS One. 2009 Aug 11;4(8):e6579.
Assessment and proposal of a new combination of screening criteria for hepatitis C in France. King LA, Le Strat Y, Meffre C, Delarocque-Astagneau E, Desenclos JC. Eur J Public Health. 2009 Aug 10. [Epub ahead of print]
Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Sato T, Tateishi R, Yoshida H, et al. Hepatol Int. 2009 Aug 6. [Epub ahead of print]
A methodology for successfully producing global translations of patient reported outcome measures for use in multiple Countries. Two R, Verjee-Lorenz A, Clayson D, et al. Value Health. 2009 Aug 20. [Epub ahead of print]
Prevalence of hepatitis C infection in New York City, 2004. Bornschlegel K, Berger M, Garg RK, et al. J Urban Health. 2009 Aug 12. [Epub ahead of print]